Harvard Bioscience (HBIO) - מכפיל EV/EBITDA
The Harvard Bioscience (HBIO) price chart on the GURU.Markets platform with the 13.18 indicator allows for an assessment of the business's dependence on the demand for high-precision biomedical equipment and order volumes from pharmaceutical behemoths. The company generates revenue through the sale of cell analysis systems and dosing pumps for laboratories. The brand's impeccable reputation among scientists and universities makes the manufacturer's position highly resilient to market volatility.
פילוחים אנליטיים של חברת Harvard Bioscience Inc. (HBIO)
For the conservative investor, this ratio serves as a key valuation metric, combining market capitalization and net debt relative to earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA trajectory of Harvard Bioscience (HBIO), one can assess the stability of HBIO: the low cyclicality of demand for laboratory equipment smooths the volatility of this multiple, confirming the fundamental reliability of the business even under a significant debt load.
